Gerald Aronoff
Pain Medicine · Charlotte, NCNPI 1144277930
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (56.3%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 39 manufacturers reported payments, led by Daiichi Sankyo Inc. at 46.1% of the total. Reporting peaked in 2019 at $10,061 and has fallen 88.5% since, to $1,158 in 2025.
Across 425 payments — averaging $39.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Daiichi Sankyo Inc.$8K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$2K
- Collegium Pharmaceutical, Inc.$1K
- AbbVie$1K
- Arbor Pharmaceuticals, Inc.$605
- Idorsia Pharmaceuticals US Inc$473
- plus $4K from 33 others
What the payments were for
- Consulting fees$6,54039%
- Travel & lodging$8035%
- Food & beverage$9,45256%
- Education$10%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$16,796 in reported general payments places this provider in the 85th percentile of 182 pain medicine providers in North Carolina.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Levorphanol Tartrate | 26 | $180,203 |
| BelbucaBuprenorphine Hcl | 28 | $24,075 |
| Xtampza ErOxycodone Myristate | 36 | $17,695 |
| HorizantGabapentin Enacarbil | 12 | $12,096 |
| Oxymorphone Hcl ErOxymorphone Hcl | 13 | $12,085 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 31 | $5,921 |
| ZtlidoLidocaine | 12 | $4,354 |
| Chlorzoxazone | 29 | $4,270 |
| Buprenorphine | 23 | $2,838 |
| Hydromorphone Hcl | 51 | $2,476 |
| Duloxetine Hcl | 104 | $1,334 |
| Lidocaine | 15 | $1,060 |
| Diclofenac Sodium | 22 | $764 |
| Methadone Hcl | 56 | $762 |
| Oxycodone Hcl | 53 | $654 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Virtus Pharmaceuticals LLCLevorphanol Tartrate | $70 | $180,20326 claims |
| Collegium Pharmaceutical, Inc.Belbuca, Xtampza Er | $1,278 | $41,77064 claims |
| Arbor Pharmaceuticals, Inc.Horizant | $605 | $12,09612 claims |
| Hikma Pharmaceuticals USABuprenorphine-Naloxone, Buprenorphine | $31 | $8,76054 claims |
| Scilex Pharmaceuticals Inc.Ztlido | $405 | $4,35412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 182 pain medicine providers in North Carolina.
Other pain medicine in Charlotte
- Jacob WangCharlotte$162K
- Aashish KumarCharlotte$160K
- James DeeringCharlotte$93K
- Ankur ManvarCharlotte$33K
- Russell DavenportCharlotte$26K
- Raza KhanCharlotte$12K
- Alexander RothkrugCharlotte$10K
- Cameron CunninghamCharlotte$8K
- James NorthWinston Salem$721K
- Leonardo KapuralWinston Salem$523K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.